GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 6, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 6, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for large public companies and typically carries low immediate risk.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc.
- August 2025 (date) — The period during which the transactions occurred.
FAQ
What was the total number of GSK plc ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased, but the specific quantity is not detailed in the provided text.
What was the total dollar amount spent on the share repurchases?
The filing does not specify the total dollar amount of the share repurchases.
On what specific date(s) in August 2025 did the share purchases occur?
The filing indicates the report is for the month of August 2025 and mentions 'Date of purcha' but does not provide specific dates for the transactions.
What is the par value of GSK plc's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Who is acting as GSK plc's corporate stockbroker for these transactions?
Merrill Lynch International is acting as GSK plc's corporate stockbroker.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 6, 2025 regarding GSK plc (GLAXF).